NVO240719C95000
- 34.88
- -5.37-13.34%
Novo-Nordisk A/S Newsroom
Express News | Shares of Weight Loss Stocks Are Trading Lower, Possibly on Continued Weakness Following Recent Weight Loss Data From Roche, Which Could Cause Competition Concerns for Companies in the Space
Novo Nordisk on Pace for Largest Percent Decrease Since February 2023 -- Data Talk
Novo Nordisk A/S Sponsored ADR Class B (NVO) is currently at $129.23, down $6.19 or 4.57% --Would be lowest close since May 10, 2024, when it closed at $128.42 --On pace for largest percent decrease
Eli Lilly's Stock Plunges as Investors Eye Obesity-drug Competition
By Eleanor Laise 'Vast' weight-loss drug pipeline keeps Lilly in a strong position as field gets crowded, analysts say Eli Lilly & Co.'s stock was on pace for its worst day in about three years
Eli Lilly, Novo Extend Muti-day Decline in Rare Selloff
European Equities Traded in the US as American Depositary Receipts Trend Lower Thursday
European equities traded in the US as American depositary receipts were moving moderately lower late Thursday morning, declining 0.72% to 1,423.26 on the S&P Europe Select ADR Index.From continental
Top Gap Ups and Downs on Wednesday: TSM, NVO, ASML and More
Gaps can show signals that something important has happened to the fundamental or the psychology of traders that accompanies this market movement.
Industry shock! Roche's new drug 'scared' the weight loss sector, causing Eli Lilly and co (LLY.US) and Novo Nordisk A/S (NVO.US) to fall.
After Roche (RHHBY.US) announced positive results from its clinical trial of oral weight-loss drugs, the share prices of Eli Lilly and Co (LLY.US) and Novo Nordisk A/S (NVO.US) fell on Wednesday.
Novo Nordisk, Eli Lilly Fall on Data From Roche's Weight-loss Pill
Big Pharma Rally After J&J Earnings
Novo Nordisk Faces Setback in Netherlands Over Wegovy Insurance Coverage
The famed Danish drug maker Novo Nordisk A/S (NYSE:NVO) expressed disappointment on Wednesday following a recommendation by the Dutch Health Care Institute advising the Netherlands government against including the company's popular weight-loss drug, Wegovy, in the basic insurance coverage.
European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading
European equities traded in the US as American depositary receipts were lower late Wednesday morning, falling 1.33% to 1,437.22 on the S&P Europe Select ADR Index.From continental Europe, the
Obesity-Drugs Focused Stocks Tumble On Wednesday - What's Going On With Eli Lilly, Novo Nordisk, Viking Therapeutics, Structure Therapeutics?
Eli Lilly And Co (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), Viking Therapeutics Inc (NASDAQ:VKTX), and Structure Therapeutics Inc (NASDAQ:GPCR) stocks are trading lower on Wednesday.What happened?
$1000 Invested In Novo Nordisk 10 Years Ago Would Be Worth This Much Today
Novo Nordisk (NYSE:NVO) has outperformed the market over the past 10 years by 8.54% on an annualized basis producing an average annual return of 19.47%. Currently, Novo Nordisk has a market
Express News | Benzinga Market Summary: Chip Stocks Fall On Fears Over China Restrictions And Soft Guidance From ASML, Roche Reports Weight Loss Data, Dragging Down Lilly And Novo Nordisk
Novartis was frightened! Roche's (RHHBY.US) clinical trial of oral weight loss drugs has achieved positive results.
Genentech, a subsidiary of Roche, stated that its oral GLP-1 receptor agonist computed tomography-996 resulted in an average weight loss of about 6% within four weeks in Phase 1 clinical trials.
Express News | Eli Lilly and Novo Nordisk Shares Are Trading Lower Following Weight Loss Data From Competitor Roche
Novo Nordisk and Eli Lilly Shares Slide on New Obesity Drug Trial From Roche
Novo Nordisk and Eli Lilly shares slid Wednesday on promising early-stage trial data from Roche's latest obesity drug candidate. Roche said its experimental once-daily pill showed average weight loss of 6.1% in four weeks. The results come as competition mounts in the fast-growing weight loss drug sector, with Roche's pill likely to provide an appealing alternative for patients who dislike injections.
Financial leverage ratio hits a new low since the financial crisis! European giants have more room for dividends and strengthening acquisitions.
Analysts predict that this year, the financial leverage of large European companies will drop to the lowest level since 2008 and the global financial crisis, which may lead to more dividends, buybacks, and mergers and acquisitions.
Dutch Health Care Wary of Reimbursing Novo Nordisk's Obesity Drug Cost
The Netherlands is unwilling to give coverage to Novo Nordisk's (NOVO-B.CO) weight loss medication Wegovy under its compulsory basic health insurance package due to its high cost and uncertainties
Top Gap Ups and Downs on Tuesday: TTE, BHP, SCHW and More
Gaps can show signals that something important has happened to the fundamental or the psychology of traders that accompanies this market movement.